Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.
Amylyx tested a medicine that might help people who get dangerous low blood sugar after weight loss surgery, and early results look promising. When a company shows their medicine works well in tests, it's a good sign they're making real progress, even though it's not guaranteed to become available.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.